Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azvudine + trimethoprim + sulfamethoxazole
- Development stage
- Preclinical
- Lead developer
- Genuine Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a combination of the nucleoside analog azvudine and the antibiotic trimethoprim-sulfamethoxazole; however, clinical and pipeline data from Genuine Biotech indicate that the intended therapeutic combination for lymphoma is **azvudine plus cyclophosphamide (CTX)**. Azvudine is a small molecule DNA synthesis inhibitor and immunomodulator that terminates DNA chain elongation in malignant cells. In the lymphoma program, it is combined with cyclophosphamide, an alkylating agent that cross-links DNA, to achieve synergistic anti-tumor effects. Preclinical studies of the azvudine/cyclophosphamide combination demonstrated complete tumor elimination in lymphoma models. Trimethoprim-sulfamethoxazole is typically used as prophylaxis against opportunistic infections (such as Pneumocystis pneumonia) in immunocompromised patients but is not the primary chemotherapy agent in this regimen.
- Brand names
- BactrimSeptra
- Other names
- Azvudine/CTXAzvudine + chemotherapy
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)Human immunodeficiency virus type 1 reverse transcriptaseDHFR (Dihydrofolate reductase)DHPS (Dihydropteroate synthase)DNA
Beyond the preview
Go deeper on azvudine + trimethoprim + sulfamethoxazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azvudine + trimethoprim + sulfamethoxazole.